| Prev Close | 301.40 |
| Day Low/High | 294.03 / 302.60 |
| 52 Wk Low/High | 193.11 / 314.00 |
Eli Lilly and Company (LLY)
295.19
NYSE
| Exchange | NYSE |
| Shares Outstanding | 950.16B |
| Market Cap | 286.38B |
| P/E Ratio | 33.79 |
| Div & Yield | N.A. (N.A) |
In a Sick Market, Can Pharmas Help?
Let's check the charts of three drug names, Merck, Eli Lilly and Bristol-Myers Squibb.
Eli Lilly's Charts Look a Bit Frail
LLY is looking shaky, despite fundamental improvements from its weight-loss drug tirzepatide.
Premarket Movers
Upside - +74% (enters strategic agreement with Immune Therapeutics for rights to low dose naltrexone) - +18% (earnings, guidance) - +16% (earnings, guidance) - +14% (earnings) - +11% (earnings, guidance) - +10% (earnings, guidance) - +9.1% (highligh...
The Good, the Bad and the Ugly, Trading Meta Platforms, What's Down Teladoc?
Wednesday's session was dominated by traders, algorithmic traders for sure, but traders nonetheless. The PMs mostly sat on their hands.
I'm Prescribing a New Approach Toward Eli Lilly as It Loses Upward Momentum
A couple bearish divergences indicate that the pace of the advance in the giant drugmaker's shares is slowing.
7 Best Buys in Biotech and Drug Development
Recently poor sector performance is creating opportunity for long-term investors.
Raising Stops on Eli Lilly as the Charts Weaken
Here's what I recommend.
Melting Candles, Meta, Spotify, Tech-Ageddon, Jobs Mess, Healthcare Hot Tickets
Just a week ago Jerome Powell referred to the labor market as 'strong.' Now, economists, traders, investors, and the public are just not quite sure what to expect Friday.
My 2022 Technical Outlook: Beware of the Treacherous Road Ahead
Unless you are a great stock picker and timer, a strategy of taking profits into available strength the next two months is key.
Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
October Rebound, Pricing In the Past, Tesla Hertz So Good, Space, Facebook Q&A
Markets are pricing in some fiscal policy, but it's not what a lot of pundits think.
What to Watch Next Week
Next Week (Selected Macro) Monday  AM: PM:  Tuesday  AM: , , , , , PM: , , ,  Wednesday  AM: , , , PM: , ,  Thursday  AM: PM: , ,  Friday  AM: , PM: none Next Week (Selected Macro)  Monday: Dallas Fed Manufacturing Index  Tuesday: Case-Sh...
While This Market Action Makes for Some Tough Trading, It's Nothing Unusual
Pockets of speculative trading are narrower, but the appetite for action has not disappeared.
Stall Speed? Jobs Gut Punch, Taiwan Worries, Mu Variant, Trading AbbVie
What if areas of expected growth in labor market demand moving forward do not materialize?
Pfizer's Charts Suggest a Strong Rally Ahead
Here are our latest price targets.
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals
Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.
Eli Lilly Is Going Strong: Here's How to Play It
Let's check out the LLY charts amid FDA approval of the company's Alzheimer's drug.
Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out
This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.
Biogen's Japanese Partner on Alzheimer's Drug Set for Gains
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Jim Cramer: Here's What Can Go Higher
Let's look at the companies that can go up, and the ones that can't.
Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell
With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.
My Favorite Day of the Month: Options Expiration Day
I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.
Jim Cramer: We've Got a Boom ... and a Bust
Let's look at this impossible move on the market -- and why health care could be coming off life support.
Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains
Let's review the charts and indicators.
